EntryPoint Capital LLC Trims Holdings in Exelixis, Inc. (NASDAQ:EXEL)

EntryPoint Capital LLC decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 54.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 8,433 shares of the biotechnology company’s stock after selling 10,230 shares during the period. EntryPoint Capital LLC’s holdings in Exelixis were worth $281,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in EXEL. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares during the period. Steward Partners Investment Advisory LLC increased its stake in Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund raised its holdings in shares of Exelixis by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares in the last quarter. Principal Securities Inc. boosted its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its holdings in shares of Exelixis by 37.3% during the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 425 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

EXEL opened at $36.84 on Friday. The stock’s 50 day moving average price is $35.70 and its 200-day moving average price is $33.14. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $40.02. The stock has a market capitalization of $10.31 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. Brookline Capital Management assumed coverage on shares of Exelixis in a report on Monday, December 23rd. They set a “buy” rating for the company. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $41.00 to $33.00 in a research report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Exelixis in a research note on Thursday. Finally, Stephens reiterated an “equal weight” rating and set a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.59.

Insider Buying and Selling

In related news, Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total value of $331,430.40. Following the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This represents a 2.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last three months. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.